Tianjin Key Laboratory On Technology Enabling Dev Of Clinical Therapeutics And Diagnostics

Tianjin, China

Tianjin Key Laboratory On Technology Enabling Dev Of Clinical Therapeutics And Diagnostics

Tianjin, China
SEARCH FILTERS
Time filter
Source Type

Zhao W.,Tianjin Key Laboratory On Technology Enabling Dev Of Clinical Therapeutics And Diagnostics | Guo W.,Tianjin Key Laboratory On Technology Enabling Dev Of Clinical Therapeutics And Diagnostics | Zhou Q.,Tianjin Key Laboratory On Technology Enabling Dev Of Clinical Therapeutics And Diagnostics | Ma S.-N.,Tianjin Key Laboratory On Technology Enabling Dev Of Clinical Therapeutics And Diagnostics | And 8 more authors.
International Journal of Molecular Sciences | Year: 2013

Tumor metastasis is the main cause of lethality of prostate cancer, because conventional therapies like surgery and hormone treatment rarely work at this stage. Tumor cell migration, invasion and adhesion are necessary processes for metastasis. By providing nutrition and an escape route from the primary site, angiogenesis is also required for tumor metastasis. Phosphatidylinositol 3-kinases (PI3Ks) are well known to play important roles in tumorigenesis as well as metastasis. ZSTK474 is a specific PI3K inhibitor developed for solid tumor therapy. In the present report, antimetastatic activities of ZSTK474 were investigated in vitro by determining the effects on the main metastatic processes. ZSTK474 exhibited inhibitory effects on migration, invasion and adhesive ability of prostate cancer PC3 cells. Furthermore, ZSTK474 inhibited phosphorylation of Akt substrate-Girdin, and the secretion of matrix metalloproteinase (MMP), both of which were reported to be closely involved in migration and invasion. On the other hand, ZSTK474 inhibited the expression of HIF-1α and the secretion of vascular endothelial growth factor (VEGF), suggesting its potential antiangiogenic activity on PC3 cells. Moreover, we demonstrated the antiangiogenesis by determining the effect of ZSTK474-reduced VEGF on tube formation of human umbilical vein endothelial cells (HUVECs). In conclusion, ZSTK474 was demonstrated to have potential in vitro antimetastatic effects on PC3 cells via dual mechanisms: inhibition of metastatic processes including cell migration, invasion and adhesion, and antiangiogenesis via blockade of VEGF secretion. © 2013 by the authors; licensee MDPI, Basel, Switzerland.

Loading Tianjin Key Laboratory On Technology Enabling Dev Of Clinical Therapeutics And Diagnostics collaborators
Loading Tianjin Key Laboratory On Technology Enabling Dev Of Clinical Therapeutics And Diagnostics collaborators